Vaccine, varicella-zoster

Generic Medicine Info
Indications and Dosage
Intramuscular, Subcutaneous
Active immunisation against varicella infection
Adult: Each 0.5 mL contains live, attenuated varicella-zoster virus (VZV) Oka/Merck strain ≥103.3 plaque-forming units (PFU), or ≥1,350 PFU: 0.5 mL for 2 doses via deep SC or IM inj, doses are given 4-8 weeks apart.
Child: 9 months to 12 years (or 1-12 years, based on product used) 0.5 mL for 2 doses via deep SC or IM inj; the 2nd dose is to be given after an interval of at least 3 months (or 6 months based on national recommendations); ≥13 years Same as adult dose.

Prevention of herpes zoster, Prevention of herpes zoster-related postherpetic neuralgia
Adult: Each 0.65 mL contains live, attenuated VZV Oka/Merck strain ≥19,400 PFU: ≥50 years 0.65 mL for 1 dose.
Reconstitute vaccine using the total volume of the provided diluent. Agitate to mix thoroughly.
Hypersensitivity. Immunosuppression or immuinodeficiency (e.g. HIV infection, leukaemia, lymphoma or other malignant neoplasms, history of primary or acquired immunodeficiency states), active infection (e.g. untreated TB). Pregnancy and lactation.
Special Precautions
Patient with mild acute illness with or without low grade fever, personal or family history of febrile convulsions.
Adverse Reactions
Significant: Syncope.
Blood and lymphatic system disorders: Lymphadenopathy.
Ear and labyrinth disorders: Otitis.
Eye disorders: Conjunctivitis.
Gastrointestinal disorders: Abdominal pain, anorexia, aphthous stomatitis, constipation, diarrhea, nausea, vomiting.
General disorders and administration site conditions: Fatigue, fever, irritability, chills, malaise; injection site reactions (e.g. erythema, bruising, haematoma, swelling).
Musculoskeletal and connective tissue disorders: Neck stiffness, arthralgia, myalgia.
Nervous system disorders: Headache.
Psychiatric disorders: Somnolence.
Reproductive system and breast disorders: Herpes labialis.
Respiratory, thoracic and mediastinal disorders: Cough, rhinitis, respiratory tract disease, pharyngitis.
Skin and subcutaneous tissue disorders: Varicella-like rashes, contact dermatitis, pruritus.
Potentially Fatal:  Severe hypersensitivity reactions (e.g. anaphylaxis).
Monitoring Parameters
Monitor for rash, fever, anaphylaxis and syncope for 15 minutes following administration.
Drug Interactions
Reduced immune response or risk of generalised infection when used concomitantly with immunosuppressants (e.g. corticosteroids). Concomitant treatment with salicylates (e.g. aspirin) may lead to Reye’s syndrome.
Lab Interference
May interfere with tuberculin tests.
Description: Varicella-zoster virus vaccine promotes immunity to varicella by inducing both cell mediated and humoral immune responses to varicella-zoster virus (VZV). It also provides strong protection against herpes zoster and herpes-zoster-related post-herpetic neuralgia (PHN) in older patients (≥50 years) by eliciting an immune response to VZV.
Onset: Seroconversion: Approx 4-6 weeks.
Duration: 10 years.
Store between 2-8°C. Do not freeze. Protect from light.
ATC Classification
J07BK - Varicella zoster vaccines ; Used for active immunizations.
Anon. Varicella Virus Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/07/2018.

Buckingham R (ed). Varicella-Zoster Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/07/2018.

Joint Formulary Committee. Varicella-Zoster Vaccines. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/07/2018.

Varivax Injection, Powder, Lyophilized, for Suspension (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/07/2018.

Zostavax (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 19/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, varicella-zoster from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in